US2010221285A1PendingUtilityA1

Method of Immunization Against the 4 Dengue Serotypes

50
Assignee: SANOFI PASTEUR SAPriority: Jul 12, 2006Filed: Mar 5, 2010Published: Sep 2, 2010
Est. expiryJul 12, 2026(~0 yrs left)· nominal 20-yr term from priority
Inventors:Veronique BarbanRemi ForratBruno GuyJean Lang
A61K 2039/5254A61K 39/12A61K 2039/5252C12N 2770/24134A61K 2039/545A61P 37/04A61P 31/12A61P 31/14A61K 2039/70Y02A50/30A61K 39/00
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a method for inducing a homologous protection against the 4 dengue serotypes in a patient, comprising the sequential administration, to said patient, (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, in which the vaccinal dengue viruses (ii) are administered at least 30 days and at most 1 year after administration of the vaccinal viruses (i).

Claims

exact text as granted — not AI-modified
1 . A vaccinal dengue virus kit comprising four different vaccinal dengue virus serotypes, wherein
 a) each vaccinal dengue virus serotype is in a separate dosage form;   b) two of the four vaccinal dengue virus serotypes are combined in a single dosage form; or   c) two of the four vaccinal dengue virus serotypes are combined in a first dosage form and the other two of the four dengue virus serotypes are combined in a second dosage form.   
     
     
         2 . The vaccinal dengue virus kit according to  claim 1  wherein the vaccinal dengue viruses serotypes are each present in the dosage forms in a range of from 10 3  to 10 5  CCID 50 . 
     
     
         3 . The vaccinal dengue virus kit as claimed in  claim 1  comprising two dosage forms, wherein two of the four serotypes are combined in a first dosage form and the other two of the four serotypes are combined in a second dosage form. 
     
     
         4 . The vaccinal dengue virus kit according to  claim 1 , wherein one of the vaccinal dengue virus serotypes is selected from the group consisting of the VDV1 strain and of a CYD DEN-1. 
     
     
         5 . The vaccinal dengue virus kit according to  claim 1  wherein one of the vaccinal dengue virus serotypes is selected from the group consisting of the VDV2 strain and of a CYD DEN-2. 
     
     
         6 . The vaccinal dengue virus kit according to  claim 1  wherein one of the vaccinal dengue virus serotypes is the VDV1 strain and another vaccinal dengue virus serotype is the VDV2 strain. 
     
     
         7 . The vaccinal dengue virus kit according to  claim 1  wherein one of the vaccinal dengue virus serotypes is CYD DEN-1 and another vaccinal dengue virus serotype is CYD DEN-2 strain. 
     
     
         8 . The dengue virus kit according to  claim 1  wherein one of the vaccinal dengue virus serotypes is a CYD DEN-3. 
     
     
         9 . The dengue virus kit according to  claim 1  wherein one of the vaccinal dengue virus serotypes is a CYD DEN-4. 
     
     
         10 . The dengue virus kit according to  claim 1  comprising the vaccinal dengue viruses CYD DEN1, CYD DEN2, CYD DEN3, and CYD DEN4, wherein each of the CYD DEN1 and CYD DEN2 serotypes are in a dosage form where each is the only dengue virus serotype in the dosage form or the two are combined together in a single dosage form, and wherein each of the CYD DEN3 and CYD DEN4 serotypes are in a dosage form where each is the only dengue virus serotype in the dosage form or the two are combined together in a single dosage form. 
     
     
         11 . A kit comprising two different vaccinal dengue virus serotypes, wherein
 a) each vaccinal dengue virus serotype is in a separate dosage form; or   b) both vaccinal dengue virus serotypes are combined in a single dosage form.   
     
     
         12 . The vaccinal dengue virus kit according to  claim 11  wherein the vaccinal dengue viruses serotypes are each present in the dosage forms in a range of from 10 3  to 10 5  CCID 50 . 
     
     
         13 . The vaccinal dengue virus kit as claimed in  claim 11  comprising two dosage forms, wherein the two serotypes are combined in a single dosage form. 
     
     
         14 . The vaccinal dengue virus kit according to  claim 11 , wherein one of the vaccinal dengue virus serotypes is selected from the group consisting of the VDV1 strain and of a CYD DEN-1. 
     
     
         15 . The vaccinal dengue virus kit according to  claim 11  wherein one of the vaccinal dengue virus serotypes is selected from the group consisting of the VDV2 strain and of a CYD DEN-2. 
     
     
         16 . The vaccinal dengue virus kit according to  claim 11  wherein one of the vaccinal dengue virus serotypes is the VDV1 strain and the other vaccinal dengue virus serotype is the VDV2 strain. 
     
     
         17 . The vaccinal dengue virus kit according to  claim 11  wherein one of the vaccinal dengue virus serotypes is CYD DEN-1 and the other vaccinal dengue virus serotype is CYD DEN-2 strain. 
     
     
         18 . The vaccinal dengue virus kit according to  claim 11  wherein one of the vaccinal dengue virus serotypes is a CYD DEN-3. 
     
     
         19 . The vaccinal dengue virus kit according to  claim 11  wherein one of the vaccinal dengue virus serotypes is a CYD DEN-4. 
     
     
         21 - 33 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.